- Home
- CPRX vs CLVT Comparison
CPRX vs CLVT Comparison
Compare CPRX & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- CLVT
- Stock Information
- Founded
- CPRX 2002
- CLVT 2016
- Country
- CPRX United States
- CLVT United Kingdom
- Employees
- CPRX N/A
- CLVT N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- CLVT EDP Services
- Sector
- CPRX Health Care
- CLVT Technology
- Exchange
- CPRX Nasdaq
- CLVT Nasdaq
- Market Cap
- CPRX 2.8B
- CLVT 2.8B
- IPO Year
- CPRX 2006
- CLVT N/A
- Fundamental
- Price
- CPRX $22.52
- CLVT $3.39
- Analyst Decision
- CPRX Strong Buy
- CLVT Hold
- Analyst Count
- CPRX 7
- CLVT 4
- Target Price
- CPRX $32.29
- CLVT $5.83
- AVG Volume (30 Days)
- CPRX 1.7M
- CLVT 6.6M
- Earning Date
- CPRX 05-07-2025
- CLVT 04-29-2025
- Dividend Yield
- CPRX N/A
- CLVT N/A
- EPS Growth
- CPRX 107.94
- CLVT N/A
- EPS
- CPRX 1.31
- CLVT N/A
- Revenue
- CPRX $491,734,000.00
- CLVT $2,556,700,000.00
- Revenue This Year
- CPRX $15.17
- CLVT N/A
- Revenue Next Year
- CPRX $9.61
- CLVT $0.67
- P/E Ratio
- CPRX $17.19
- CLVT N/A
- Revenue Growth
- CPRX 23.49
- CLVT N/A
- 52 Week Low
- CPRX $14.47
- CLVT $3.04
- 52 Week High
- CPRX $26.16
- CLVT $7.31
- Technical
- Relative Strength Index (RSI)
- CPRX 48.15
- CLVT 39.97
- Support Level
- CPRX $21.93
- CLVT $3.04
- Resistance Level
- CPRX $23.27
- CLVT $3.58
- Average True Range (ATR)
- CPRX 1.27
- CLVT 0.26
- MACD
- CPRX -0.14
- CLVT 0.01
- Stochastic Oscillator
- CPRX 50.60
- CLVT 33.98
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.